Provided by Tiger Trade Technology Pte. Ltd.

Clinuvel Pharmaceuticals Ltd.

7.80
0.0000
Post-market: 7.800.00000.00%19:30 EDT
Volume:206
Turnover:1.60K
Market Cap:393.34M
PE:18.89
High:7.78
Open:7.78
Low:7.78
Close:7.80
52wk High:9.00
52wk Low:5.98
Shares:50.43M
Float Shares:43.88M
Volume Ratio:0.02
T/O Rate:0.00%
Dividend:0.03
Dividend Rate:0.44%
EPS(TTM):0.4130
EPS(LYR):0.4707
ROE:13.96%
ROA:10.62%
PB:2.20
PE(LYR):16.57

Loading ...

Company Profile

Company Name:
Clinuvel Pharmaceuticals Ltd.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
16
Office Location:
535 Bourke Street,Level 22,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9660 4909
Introduction:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Directors

Name
Position
Guy van Dievoet
Non-Executive Director
Jeffrey Rosenfeld
Chair of the Board and Non-Executive Director
Karen Agersborg
Non-Executive Director
Matthew Pringle
Non-Executive Director
Pearl Grimes
Non-Executive Director
Susan Smith
Non-Executive Director

Shareholders

Name
Position
Philippe Wolgen
Chief Executive Officer and Managing Director
Lachlan Hay
Chief Operating Officer
Peter Vaughan
Chief Financial Officer
Dennis Wright
Chief Scientific Officer